US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gene Editing

391.98

+5.801.50%

Number of Gainers:6

Number of Losers:- -

Number of Flat:- -

PE:- -

High:395.96

Open:386.50

Low:378.08

Close:386.19

Loading ...

Shareholders in CRISPR Therapeutics (NASDAQ:CRSP) are in the red if they invested a year ago

Simply Wall St.

Intellia Therapeutics initiated with a Buy at H.C. Wainwright

Intellia Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $30

THOMSON REUTERS

Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14%

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics: Promising Potential in Biotech with NTLA-2002 Advancements and Strategic Focus

Beam Therapeutics Inc : Scotiabank Raises Target Price to $25 From $24

THOMSON REUTERS

Top Executive Makes Bold Move with Major Stock Purchase!

Sangamo Therapeutics (NASDAQ:SGMO shareholders incur further losses as stock declines 15% this week, taking five-year losses to 89%

Simply Wall St.

3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.

Intellia Therapeutics Inc : JP Morgan Cuts to Neutral From Overweight; Cuts Target Price to $13 From $45

THOMSON REUTERS

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Cullinan Management (CGEM)

Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Intellia Therapeutics (NTLA)

Cautious Optimism for Beam Therapeutics Amid Upcoming Milestones and Financial Considerations

Intellia Therapeutics Delivers a Q4 Beat

Intellia Therapeutics Q4 Net Loss Narrows; Shares Rise Pre-Bell

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4556/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4556"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":391.98187,"timestamp":1741202963673,"preClose":386.18573,"halted":0,"volume":13555511,"delay":0,"changeRate":0.015009,"change":5.796143,"pbRate":1.873032,"amount":79606814.860621,"amplitude":0.046291,"prevYearClose":376.62552,"fiveDayClose":408.0821,"twentyDayClose":376.4462,"turnoverRate":0.024836,"marketCap":7282460028,"floatMarketCap":6832329180,"peRate":-3.692897},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":395.95972,"amplitude":0.046291,"preClose":386.18573,"low":378.08292,"pbRate":"1.873032","latestPrice":391.98187,"volume":13555522,"delay":0,"open":386.49673,"prevYearClose":376.62552,"prevWeekClose":396.1103,"prevMonthClose":396.1103,"prevQuarterClose":376.6255,"fiveDayClose":408.0821,"twentyDayClose":376.4462,"sixtyDayClose":408.5231,"secType":"PLATE","market":"US","turnoverRate":0.024836,"peRate":-3.692897,"marketCap":7282460028,"floatMarketCap":6832329180,"timestamp":1741202964442,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":6,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517947644","title":"Shareholders in CRISPR Therapeutics (NASDAQ:CRSP) are in the red if they invested a year ago","url":"https://stock-news.laohu8.com/highlight/detail?id=2517947644","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517947644?lang=en_us&edition=fundamental","pubTime":"2025-03-06 01:04","pubTimestamp":1741194247,"startTime":"0","endTime":"0","summary":"Investors can approximate the average market return by buying an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. Investors in CRISPR Therapeutics AG  have tasted that bitter downside in the last year, as the share price dropped 46%. That contrasts poorly with the market return of 15%. At least the damage isn't so bad if you look at the last three years, since the stock is down 28% in that time. Shareholders have had an even rougher run lately, with the share price down 15% in the last 90 days. However, one could argue that the price has been influenced by the general market, which is down 6.0% in the same timeframe.So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress.Check out our latest analysis for CRISPR Therapeutics","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shareholders-crispr-therapeutics-nasdaq-crsp-170407662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BKPKM429.USD","USJW.SI","TQQQ","NVIW.SI","USAW.SI","BK4139","LU2210150020.SGD","MNQmain","BK4112","IE00B64PRP62.GBP","QLD","LU2095319765.USD","IE00BGHQF748.EUR","NQmain","BK4585","PSQ","TSYW.SI","IE00B3QW5Z07.USD","LU1861559042.SGD","BK4556","NDAQ","LU1861558580.USD","LU2210149790.SGD","SQQQ","BK4588","QID","CRSP",".IXIC"],"gpt_icon":1},{"id":"2517099048","title":"Intellia Therapeutics initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2517099048","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517099048?lang=en_us&edition=fundamental","pubTime":"2025-03-05 19:10","pubTimestamp":1741173043,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Intellia Therapeutics (NTLA) with a Buy rating and $30 price target Intellia is a gen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","LU1861559042.SGD","BK4556","NTLA","BK4585","BK4535","LU1861558580.USD"],"gpt_icon":0},{"id":"2517799701","title":"Intellia Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating  and Target Price $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2517799701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517799701?lang=en_us&edition=fundamental","pubTime":"2025-03-05 19:06","pubTimestamp":1741172816,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nAZN3I0IJP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4535","BK4588","LU1861559042.SGD","LU1861558580.USD","NTLA","BK4556","BK4139"],"gpt_icon":0},{"id":"2517937006","title":"Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517937006","media":"Benzinga","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517937006?lang=en_us&edition=fundamental","pubTime":"2025-03-05 10:00","pubTimestamp":1741140044,"startTime":"0","endTime":"0","summary":"Cathie Wood is back in the spotlight, and so is her flagship ARK Innovation ETF . After a rough year, the fund is showing signs of life—but is this the start of a real comeback, or just another short-lived rally?Investors are split, and the numbers tell an interesting story.ARKK's Rebound, Skeptics, and the High-Stakes Bet on Innovation. So far this year, ARKK is up 6%—a solid lead over the S&P 500's 2% gain and the Nasdaq's 1% increase. That's a welcome shift after 2024, when ARKK returned 12%—not bad, but nowhere near the S&P 500's 24% surge.The $1.3 Billion Startup Investment Boom: How This Company's Explosive Growth Is Opening Doors For Everyday Investors With A New $500 Minimum. ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.26/share with a $1000 minimum.ARK now holds nearly 7.7 million shares of Beam, making up 8.54% of the company's outstanding stock. That investment places Beam as ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cathie-woods-bold-move-8-020044301.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4559","BK4505","BK4535","VOO","BK4585","SDS","SPY","BK4550","BK4544","UPRO",".SPX","BEAM","IVV","BK4556","SPXU","ARKK","ESmain","BK4581","BK4534","SSO","SH","BK4588","BK4504","OEF","LENZ","BK4139","OEX"],"gpt_icon":0},{"id":"2517052986","title":"Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517052986","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517052986?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:01","pubTimestamp":1741122060,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., March  04, 2025  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/04/3036929/0/en/Intellia-Therapeutics-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".IXIC","LU1861559042.SGD","MNQmain","USJW.SI","USAW.SI","BK4556","SQQQ","TQQQ","IE00BKPKM429.USD","LU2210150020.SGD","BK4139","BK4112","IE00B3QW5Z07.USD","CRSP","IE00BGHQF748.EUR","BK4585","QID","LU2210149790.SGD","NDAQ","IE00B64PRP62.GBP","NTLA","TSYW.SI","NQmain","NVIW.SI","PSQ","LU1861558580.USD","LU2095319765.USD","BK4535","QLD","BK4588"],"gpt_icon":1},{"id":"2516065987","title":"Intellia Therapeutics: Promising Potential in Biotech with NTLA-2002 Advancements and Strategic Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2516065987","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516065987?lang=en_us&edition=fundamental","pubTime":"2025-03-04 01:16","pubTimestamp":1741022160,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Joon Lee maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of $50.00....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/intellia-therapeutics-promising-potential-in-biotech-with-ntla-2002-advancements-and-strategic-focus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/intellia-therapeutics-promising-potential-in-biotech-with-ntla-2002-advancements-and-strategic-focus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","LU1861559042.SGD","NTLA","BK4588","BK4139","BK4535","BK4585","BK4556"],"gpt_icon":0},{"id":"2516363819","title":"Beam Therapeutics Inc : Scotiabank Raises Target Price to  $25 From $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2516363819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516363819?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:41","pubTimestamp":1741005666,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM0OP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BEAM","BK4556","BK4139","BK4505","BK4585","BK4535","BK4588"],"gpt_icon":0},{"id":"2516758475","title":"Top Executive Makes Bold Move with Major Stock Purchase!","url":"https://stock-news.laohu8.com/highlight/detail?id=2516758475","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516758475?lang=en_us&edition=fundamental","pubTime":"2025-03-01 10:12","pubTimestamp":1740795165,"startTime":"0","endTime":"0","summary":"New insider activity at Crispr Therapeutics AG ( ($CRSP) ) has taken place on March 1, 2025. John Greene, the Executive Vice President and Chief Fi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executive-makes-bold-move-with-major-stock-purchase-10?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executive-makes-bold-move-with-major-stock-purchase-10?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","BK4588","LU1861558580.USD","BK4585","LU1861559042.SGD","CRSP","BK4139"],"gpt_icon":0},{"id":"2514291973","title":"Sangamo Therapeutics (NASDAQ:SGMO shareholders incur further losses as stock declines 15% this week, taking five-year losses to 89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514291973","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514291973?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:38","pubTimestamp":1740746319,"startTime":"0","endTime":"0","summary":"Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see fellow investors lose their hard-earned money. For example, we sympathize with anyone who was caught holding Sangamo Therapeutics, Inc.  during the five years that saw its share price drop a whopping 89%. The falls have accelerated recently, with the share price down 58% in the last three months. We really feel for shareholders in this scenario. It's a good reminder of the importance of diversification, and it's worth keeping in mind there's more to life than money, anyway.After losing 15% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance.Check out our latest analysis for Sangamo Therapeutics. But note: Sangamo Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with past earn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sangamo-therapeutics-nasdaq-sgmo-shareholders-123839080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SGMO","TSYW.SI","SQQQ","BK4588","IE00BKPKM429.USD","BK4112","LU2095319765.USD","PSQ","USJW.SI","BK4556","QID","IE00BGHQF748.EUR","TQQQ","NVIW.SI","BK4139","IE00B64PRP62.GBP","BK4585","MNQmain",".IXIC","IE00B3QW5Z07.USD","LU2210150020.SGD","NQmain","USAW.SI","LU2210149790.SGD","QLD","NDAQ"],"gpt_icon":1},{"id":"2514146543","title":"3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.","url":"https://stock-news.laohu8.com/highlight/detail?id=2514146543","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514146543?lang=en_us&edition=fundamental","pubTime":"2025-02-28 15:15","pubTimestamp":1740726900,"startTime":"0","endTime":"0","summary":"Biotech stocks offer investors a great way to get in on innovation and growth.These three players may be ripe for a rebound thanks to their solid pipelines.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/02/28/3-biotech-stocks-to-buy-before-they-soar/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4588","BK4585","CRSP","BK4556","BK4139","LU1861558580.USD","LU1861559042.SGD"],"gpt_icon":1},{"id":"2514399570","title":"Intellia Therapeutics Inc : JP Morgan Cuts to Neutral From Overweight; Cuts Target Price to $13 From $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2514399570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514399570?lang=en_us&edition=fundamental","pubTime":"2025-02-28 13:14","pubTimestamp":1740719652,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI27Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861558580.USD","LU1861559042.SGD","BK4139","NTLA","BK4535","BK4588","BK4556","BK4585"],"gpt_icon":0},{"id":"2514316337","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Cullinan Management (CGEM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514316337","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514316337?lang=en_us&edition=fundamental","pubTime":"2025-02-28 04:30","pubTimestamp":1740688204,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Intellia Therapeutics (NTLA – Research Report) and Cullinan Manag...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-intellia-therapeutics-ntla-and-cullinan-management-cgem?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-intellia-therapeutics-ntla-and-cullinan-management-cgem?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","NTLA","BK4585","CGEM","BK4588","BK4535","LU1861559042.SGD","BK4137","LU1861558580.USD","HCSG","BK4139"],"gpt_icon":0},{"id":"2514780334","title":"Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Intellia Therapeutics (NTLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514780334","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514780334?lang=en_us&edition=fundamental","pubTime":"2025-02-28 04:00","pubTimestamp":1740686416,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ironwood Pharma (IRWD – Research Report) and Intelli...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ironwood-pharma-irwd-and-intellia-therapeutics-ntla?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ironwood-pharma-irwd-and-intellia-therapeutics-ntla?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","NTLA","IRWD","BK4585","BK4137","BK4588","LU1861559042.SGD","BK4556","HCSG","BK4535","BK4139"],"gpt_icon":0},{"id":"2514800573","title":"Cautious Optimism for Beam Therapeutics Amid Upcoming Milestones and Financial Considerations","url":"https://stock-news.laohu8.com/highlight/detail?id=2514800573","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514800573?lang=en_us&edition=fundamental","pubTime":"2025-02-28 00:45","pubTimestamp":1740674715,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy has maintained their neutral stance on BEAM stock, giving a Hold rating yesterday. Soumit Roy has given his Hold ra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cautious-optimism-for-beam-therapeutics-amid-upcoming-milestones-and-financial-considerations?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cautious-optimism-for-beam-therapeutics-amid-upcoming-milestones-and-financial-considerations?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BEAM","BK4585","BK4588","BK4505","BK4556","BK4535","LENZ"],"gpt_icon":0},{"id":"2514838714","title":"Intellia Therapeutics Delivers a Q4 Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2514838714","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514838714?lang=en_us&edition=fundamental","pubTime":"2025-02-27 23:35","pubTimestamp":1740670500,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics reported better-than-expected results for the fourth quarter thanks to a boost in its collaboration revenue. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/data-news/2025/02/27/intellia-therapeutics-surges-in-revenue/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1861558580.USD","LU1861559042.SGD","NTLA","BK4588","BK4139","BK4535","BK4585","BK4556"],"gpt_icon":0},{"id":"2514388006","title":"Intellia Therapeutics Q4 Net Loss Narrows; Shares Rise Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2514388006","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514388006?lang=en_us&edition=fundamental","pubTime":"2025-02-27 22:22","pubTimestamp":1740666161,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics  reported a Q4 net loss Thursday of $1.27 per diluted share, narrower than a loss of $1.46 a year earlier.Analysts polled by FactSet expected a loss of $1.33.Collaboration revenue for the quarter ended Dec. 31 was $12.9 million, compared with a revenue loss of $1.9 million a year earlier.Analysts surveyed by FactSet expected $8.6 million.The company said it had cash, cash equivalents and marketable securities of $861.7 million as of Dec. 31, which is expected to fund operations into H1 2027.Intellia shares were rising past 5% in recent premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTLA","BK4588","BK4535","BK4556","LU1861558580.USD","LU1861559042.SGD","BK4139","BK4585"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":1,"totalSize":58}]}}